BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
Stocks · News reference
Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations but lowers guidance. Other stocks dip in pre-market.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases
Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5
Shares of communications services are trading higher after AI executives from firms including Anthropic, OpenAI and SpaceXAI signaled that the industry's growth may have to be slowed, which may limit competition in content creation, advertising sales and other areas. The sector's cash flow from ads and subscription revenue may also be attractive to investors amid elevated bond yields, inflation fears and interest rate expectations.
Morgan Stanley Maintains Overweight on AppLovin, Lowers Price Target to $450
Morgan Stanley analyst Matthew Cost maintains AppLovin (NASDAQ:APP) with a Overweight and lowers the price target from $650 to $450.
Jim Cramer Recommends Buying This Communication Services Stock, Calling It ‘Amazing’
Cramer backs Sphere and Cameco, urges selling AppLovin, criticizes Honeywell and QXO, and sees limited-risk upside in Aflac.